Literature DB >> 22072315

Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006.

Laszlo Lakatos1, Lajos S Kiss, Gyula David, Tunde Pandur, Zsuzsanna Erdelyi, Gabor Mester, Mihaly Balogh, Istvan Szipocs, Csaba Molnar, Erzsebet Komaromi, Peter Laszlo Lakatos.   

Abstract

BACKGROUND: Recent trends indicate a change in the epidemiology of inflammatory bowel diseases (IBD), with previously low incidence areas now reporting a progressive rise in the incidence. Our aim was to analyze the incidence and disease phenotype at diagnosis in IBD in the population-based Veszprem Province database, which included incident patients diagnosed between January 1, 2002 and December 31, 2006.
METHODS: Data of 393 incident patients were analyzed (ulcerative colitis [UC]: 220, age-at-diagnosis: 40.5 years; Crohn's disease [CD]: 163, age-at-diagnosis: 32.5 years; and indeterminate colitis [IC]: 10). Both hospital and outpatient records were collected and comprehensively reviewed.
RESULTS: Adjusted mean incidence rates were 8.9/10(5) person-years for CD and 11.9/10(5) person-years in UC. Peak onset age in both CD and UC patients was 21-30 years old. Location at diagnosis in UC was proctitis in 26.8%, left-sided colitis in 50.9%, and pancolitis in 22.3%. The probability of proximal extension and colectomy after 5 years was 12.7% and 2.8%. The disease location in CD was ileal in 20.2%, colonic in 35.6%, ileocolonic in 44.2%, and upper gastrointestinal in four patients. Behavior at diagnosis was stenosing/penetrating in 35.6% and perianal in 11.1%. Patients with colonic disease were older at diagnosis compared to patients with ileal or ileocolonic disease. In a Kaplan-Meier analysis, probability of surgical resection was 9.8%, 18.5%, and 21.3% after 1, 3, and 5 years of disease duration, respectively.
CONCLUSIONS: The incidence of IBD in Veszprem Province in the last decade was high, equal to that in high-incidence areas in Western European countries. Early disease course is milder compared to data reported in the literature.
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 22072315     DOI: 10.1002/ibd.21607

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  40 in total

Review 1.  Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe.

Authors:  Fanni Rencz; Márta Péntek; Martin Bortlik; Edyta Zagorowicz; Tibor Hlavaty; Andrzej Śliwczyński; Mihai M Diculescu; Limas Kupcinskas; Krisztina B Gecse; László Gulácsi; Peter L Lakatos
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

2.  Inflammatory bowel disease in an underdeveloped region of Northeastern Brazil.

Authors:  José Miguel Luz Parente; Claudio Saddy Rodrigues Coy; Viriato Campelo; Mírian Perpétua Palha Dias Parente; Leonardo Araújo Costa; Renata Mendes da Silva; Celso Stephan; José Murilo Robilotta Zeitune
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

3.  Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review.

Authors:  Mathurin Fumery; Siddharth Singh; Parambir S Dulai; Corinne Gower-Rousseau; Laurent Peyrin-Biroulet; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2017-06-16       Impact factor: 11.382

4.  Is early limited surgery associated with a more benign disease course in Crohn's disease?

Authors:  Petra Anna Golovics; Laszlo Lakatos; Attila Nagy; Tunde Pandur; Istvan Szita; Mihaly Balogh; Csaba Molnar; Erzsebet Komaromi; Barbara Dorottya Lovasz; Michael Mandel; Gabor Veres; Lajos S Kiss; Zsuzsanna Vegh; Peter Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

5.  Lack of utility of symptoms and signs at first presentation as predictors of inflammatory bowel disease in secondary care.

Authors:  Alexander C Ford; Paul Moayyedi; Premysl Bercik; David G Morgan; Carolina Bolino; Maria I Pintos-Sanchez; Walter Reinisch
Journal:  Am J Gastroenterol       Date:  2015-04-28       Impact factor: 10.864

Review 6.  Where are we on worms?

Authors:  David E Elliott; Joel V Weinstock
Journal:  Curr Opin Gastroenterol       Date:  2012-11       Impact factor: 3.287

7.  Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis.

Authors:  Sander van der Marel; Anna Majowicz; Karin Kwikkers; Richard van Logtenstein; Anje A te Velde; Anne S De Groot; Sybren L Meijer; Sander J van Deventer; Harald Petry; Daniel W Hommes; Valerie Ferreira
Journal:  World J Gastroenterol       Date:  2012-08-28       Impact factor: 5.742

8.  Evolution of disease phenotype in adult and pediatric onset Crohn's disease in a population-based cohort.

Authors:  Barbara Dorottya Lovasz; Laszlo Lakatos; Agnes Horvath; Istvan Szita; Tunde Pandur; Michael Mandel; Zsuzsanna Vegh; Petra Anna Golovics; Gabor Mester; Mihaly Balogh; Csaba Molnar; Erzsebet Komaromi; Lajos Sandor Kiss; Peter Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

9.  Similar risk of depression and anxiety following surgery or hospitalization for Crohn's disease and ulcerative colitis.

Authors:  Ashwin N Ananthakrishnan; Vivian S Gainer; Tianxi Cai; Raul Guzman Perez; Su-Chun Cheng; Guergana Savova; Pei Chen; Peter Szolovits; Zongqi Xia; Philip L De Jager; Stanley Shaw; Susanne Churchill; Elizabeth W Karlson; Isaac Kohane; Roy H Perlis; Robert M Plenge; Shawn N Murphy; Katherine P Liao
Journal:  Am J Gastroenterol       Date:  2013-01-22       Impact factor: 10.864

Review 10.  Microbiome-Epigenome Interactions and the Environmental Origins of Inflammatory Bowel Diseases.

Authors:  Tatiana Y Fofanova; Joseph F Petrosino; Richard Kellermayer
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-02       Impact factor: 2.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.